Nail Diseases (Nail Disease)

1.	Scher, Richard K: 2 articles (02/2008 - 04/2006)
2.	Nestle, Frank O: 1 article (02/2008)
3.	Griffiths, Christopher E M: 1 article (02/2008)
4.	Reich, Kristian: 1 article (02/2008)
5.	Rich, Phoebe: 1 article (02/2008)
6.	Li, Shu: 1 article (02/2008)
7.	Hsu, Ming-Chun: 1 article (02/2008)
8.	Xu, Stephen: 1 article (02/2008)
9.	Guzzo, Cynthia: 1 article (02/2008)
10.	Elewski, Boni E: 1 article (04/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nail Diseases:

1.	diazenedicarboxylic acid bis(N'-methylpiperazide)IBA 08/01/1999 - "Patients with psoriatic nail disease (180/221, 81%) had significantly greater number of involved distal interphalangeal (DIP) joints (p = 0.004)" 09/01/1994 - "The topographic association of nail disease and involvement of the adjacent DIP joints suggests a common local inflammatory mechanism." 09/01/1994 - "Nail disease (67% of total) was more common in patients with DIP joint disease (27% of total) and was significantly associated with adjacent DIP joint disease" 06/01/2000 - "There was a significant (P < 0.05) decrease in capillary loop density in patients with either psoriasis plus nail disease (14.5 +/- 5.7 capillaries per 3 mm field) or psoriasis plus nail and DIP joint disease (14.3 +/- 5. 0) when compared with controls (19.2 +/- 3.8)" 12/01/1989 - "Thirteen patients showed some features of psoriatic arthritis, including 5 with suspected skin or nail disease, 5 with a family history of psoriasis, 3 with DIP joint affliction, and 2 with aortic valve insufficiency" Order ALL the reference details at left...
2.	infliximab (Remicade)FDA Link 08/01/2008 - "CONCLUSIONS: Alphalthough there is no control group, this data suggests that infliximab is effective for psoriatic nail disease in the context of severe skin and joint involvement." 02/01/2008 - "Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P < .001)" 02/01/2008 - "Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year." Order ALL the reference details at left...
3.	Ketoconazole (Nizoral)FDA LinkGeneric 12/01/1980 - "All six recipients of ketoconazole had remission of symptoms and virtually complete regression of mucosal, skin, and nail lesions, whereas only two of the six receiving placebo had even temporary mucosal clearing, and none had improvement of skin or nail disease" Order ALL the reference details at left...
4.	Immunosuppressive Agents (Immunosuppressants)IBA 12/01/2004 - "Systemic corticosteroids and adjuvant immunosuppressants were effective in treating mucocutaneous lesions as well as nail disease" Order ALL the reference details at left...
5.	FumaratesIBA 01/01/2007 - "We present a case of psoriatic nail disease which improved greatly on treatment with fumaric acid esters (FAE)." Order ALL the reference details at left...
6.	Adrenal Cortex Hormones (Corticosteroids)IBA 12/01/2004 - "Systemic corticosteroids and adjuvant immunosuppressants were effective in treating mucocutaneous lesions as well as nail disease" Order ALL the reference details at left...
7.	alefacept (Amevive)FDA Link 04/01/2006 - "Alefacept in the treatment of psoriatic nail disease: a proof of concept study." 06/01/2005 - "Alefacept in the treatment of psoriatic nail disease: a small case series." 04/01/2006 - "Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be?" Order ALL the reference details at left...
8.	Keratins (Keratin)IBA 03/01/1996 - "Extension of this observation to human hereditary hair and nail diseases includes population analyses of human hair keratin genes for natural sequence variations in the corresponding sites" 12/01/1995 - "This is the first mapping of a primary human hair disorder and the first evidence implicating a defect of the word 'hard' keratins of hair and nail disease." 09/01/2007 - "BACKGROUND: Topical treatment of nail diseases is hampered by the nail plate barrier, consisting of dense cross-linked keratin fibres held together by cysteine-rich proteins and disulphide bonds, which prevents penetration of antifungal agents to the focus of fungal infection" Order ALL the reference details at left...
9.	HLA-B27 Antigen (HLA B27 Antigen)IBA 02/01/2000 - "We and others have previously described development of spontaneous arthritis and nail disease in HLA-B27 transgenic animals" 02/01/1999 - "We have previously reported spontaneous arthritis and nail disease in HLA-B27 transgenic mice lacking beta2-microglobulin (B27+beta2m(o))" Order ALL the reference details at left...
10.	Antifungal AgentsIBA 12/01/2005 - "Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality." 09/01/2007 - "BACKGROUND: Topical treatment of nail diseases is hampered by the nail plate barrier, consisting of dense cross-linked keratin fibres held together by cysteine-rich proteins and disulphide bonds, which prevents penetration of antifungal agents to the focus of fungal infection" Order ALL the reference details at left...

Therapies and Procedures

1.	Lasers (Laser) 01/01/1989 - "Clinical trials evidence the efficacy of laser treatment as a component of multiple-modality therapy of nail diseases of various etiology" Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 02/01/2004 - "CONCLUSION: Hemodialysis patients and renal transplant recipients have higher rates of nail disease than the healthy population" Order ALL the reference details at left...
3.	Renal Dialysis (Hemodialysis) 02/01/2004 - "CONCLUSION: Hemodialysis patients and renal transplant recipients have higher rates of nail disease than the healthy population" Order ALL the reference details at left...
4.	Biological Therapy 01/01/2007 - "Biological therapy for psoriasis and psoriatic arthritis is now widely used, and early evidence indicates it may have significant benefit for some patients with psoriatic nail disease" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Nail Diseases

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 6 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>